Table 4.
Overall and event-free survival by patient group
| Patient group | Overall survival,3-year % (95% CI) | Event-free survival,3-year % (95% CI) |
|---|---|---|
| All | 60 (51-71) | 40 (31-52) |
| Donor graft | ||
| Related | 70 (58-83) | 47 (35-63) |
| Unrelated | 47 (33-67) | 32 (20-52) |
| Diagnosis | ||
| Lymphoid | 69 (58-82) | 42 (30-56) |
| Myeloid | 47 (33-67) | 40 (27-59) |
| Age | ||
| Lymphoid | ||
| < 55 y | 65 (51-82) | 42 (29-61) |
| ≤ 55 y | 80 (61-100) | 41 (22-78) |
| Myeloid | ||
| < 55 y | 47 (29-78) | 30 (15-59) |
| ≤ 55 y* | 48 (31-76) | 49 (32-75) |
| Disease status at the start of conditioning | ||
| Non-Hodgkin lymphoma | ||
| CR | 92 (79-100) | 36 (13-96) |
| PR | 76 (63-92) | 53 (38-73) |
| SD or PD* | 0 | 12 (2-78) |
| De novo AML | ||
| CR1 | 50 (33-77) | 48 (31-73) |
| CR2 | 37 (14-100) | 50 (27-93) |
| Other† | 20 (3-100) | 0 |
| Chimerism | ||
| NHL in CR or PR at start of TLI and ATG | ||
| Complete donor chimerism | 81 (69-93) | 74 (57-91) |
| Mixed donor chimerism | 72 (36-100) | 0 |
| De novo AML in CR1 or CR2 at start of TLI and ATG | ||
| Complete donor chimerism | 64 (42-86) | 64 (43-84) |
| Mixed donor chimerism | 25 (0-55) | 25 (0-56) |
| Primary graft failure | 0 | 0 |
| Prior autologous HCT | ||
| NHL with prior autologous HCT | 75 (58-95) | 41 (25-69) |
| NHL without prior autologous HCT | 73 (56-95) | 46 (27-76) |
CI indicates confidence interval; HCT, hematopoietic cell transplantation; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; CR, complete remission; PR, partial remission; SD, stable disease; and PD, progressive disease.
*
The OS falls below the EFS as an artifact of censoring subject(s) between the times of another subject's relapse and death.
†
Other, beyond 2nd CR, partial response, stable disease, or progressive disease.